| Ident. | Authors (with country if any) | Title |
|---|
| 000208 (2020) |
Natalia Maximova [Italie] ; Alessandra Maestro [Italie] ; Davide Zanon [Italie] ; Annalisa Marcuzzi [Italie] | Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration |
| 000837 (2019) |
Yun-Chi Lu [Taïwan] ; Chih-Hung Chuang [Taïwan] ; Kuo-Hsiang Chuang [Taïwan] ; I-Ju Chen [Taïwan] ; Bo-Cheng Huang [Taïwan] ; Wen-Han Lee [Taïwan] ; Hsin-Ell Wang [Taïwan] ; Jia-Je Li [Taïwan] ; Yi-An Cheng [Taïwan] ; Kai-Wen Cheng [Taïwan] ; Jaw-Yuan Wang [Taïwan] ; Yuan-Chin Hsieh [Taïwan] ; Wen-Wei Lin [Taïwan] ; Tian-Lu Cheng [Taïwan] | Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy |
| 000985 (2019) |
Vincent Chow ; Myungshin Oh ; Melissa A. Gessner ; Gary Fanjiang | Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Subjects |
| 000A42 (2019) |
Chiharu Iwahashi [Japon] ; Hikari Ono [Japon] ; Mami Haruta [Japon] ; Takamasa Minami [Japon] ; Hisashi Mashimo [Japon] ; Hiroshi Shimojo [Japon] ; Nobuyuki Ohguro [Japon] | New onset or exacerbation of uveitis with infliximab: paradoxical effects? |
| 000B69 (2019) |
Mélanie Rinaudo-Gaujous ; Vincent Blasco-Baque ; Pierre Miossec ; Philippe Gaudin ; Pierre Farge ; Xavier Roblin ; Thierry Thomas [France] ; Stephane Paul ; Hubert Marotte [France] | Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients |
| 000D33 (2019) |
Virginia Miraldi Utz [États-Unis] ; Sabrina Bulas [États-Unis] ; Sarah Lopper [États-Unis] ; Matthew Fenchel [États-Unis] ; Ting Sa [États-Unis] ; Mitul Mehta [États-Unis] ; Daniel Ash [États-Unis] ; Daniel J. Lovell [États-Unis] ; Adam H. Kaufman [États-Unis] | Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis |
| 001032 (2019) |
Viveka Clare De Guerra [États-Unis] ; Humaira Hashmi [États-Unis] ; Bree Kramer [États-Unis] ; Rula Balluz [États-Unis] ; Mary Beth Son [États-Unis] ; Deborah Stein [États-Unis] ; Alicia Lieberman [États-Unis] ; Mahmoud Zahra [États-Unis] ; Rabheh Abdul-Aziz [États-Unis] | A Case Report of Takayasu's Arteritis and Ulcerative Colitis in a Pediatric Patient with Chronic Recurrent Multifocal Osteomyelitis Successfully Treated with Infliximab: Diagnostic Clues in Disease Associations and Immune Dysregulation |
| 001185 (2018) |
Shun Tanimura [Japon] ; Masaru Kato [Japon] ; Nobuya Abe [Japon] ; Hiroshi Ohira [Japon] ; Ichizo Tsujino [Japon] ; Tatsuya Atsumi [Japon] | Successful treatment of tocilizumab-resistant large vessel pulmonary arteritis with infliximab. |
| 001335 (2018) |
Kazuha Kizaki [Japon] ; Fumiharu Yamashita [Japon] ; Tomoya Hayashi [Japon] ; Noboru Funakoshi [Japon] | Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis. |
| 001390 (2018) |
Masataka Umeda [Japon] ; Tomohiro Koga [Japon] ; Kunihiro Ichinose [Japon] ; Ayuko Takatani [Japon] ; Takashi Igawa [Japon] ; Toshimasa Shimizu [Japon] ; Shoichi Fukui [Japon] ; Ayako Nishino [Japon] ; Yoshiro Horai [Japon] ; Yasuko Hirai [Japon] ; Shin-Ya Kawashiri [Japon] ; Naoki Iwamoto [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Tomoki Origuchi [Japon] ; Toshiyuki Aramaki [Japon] ; Yukitaka Ueki [Japon] ; Akitomo Okada [Japon] ; Keita Fujikawa [Japon] ; Naoki Matsuoka [Japon] ; Atsushi Kawakami [Japon] | Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice. |
| 001405 (2018) |
Aly M. Abdelrahman [Oman] ; Yousuf M. Al Suleimani [Oman] ; Mohammed Ashique [Oman] ; Priyadarsini Manoj [Oman] ; Badreldin H. Ali [Oman] | Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats. |
| 001790 (2017) |
Mohammed I. Aladul [Royaume-Uni] ; Raymond W. Fitzpatrick [Royaume-Uni] ; Stephen R. Chapman [Royaume-Uni] | Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. |
| 001920 (2017) |
Tim A. Kanters [Pays-Bas] ; Jelena Stevanovic [Belgique, Pays-Bas] ; Isabelle Huys [Belgique] ; Arnold G. Vulto [Pays-Bas] ; Steven Simoens [Belgique] | Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel |
| 001B81 (2016) |
Tomoya Hirota [Japon] ; Takeshi Suzuki [Japon] ; Hiroshi Ogishima [Japon] ; Shinya Hagiwara [Japon] ; Hiroshi Ebe [Japon] ; Hiroyuki Takahashi [Japon] ; Masahiro Yokosawa [Japon] ; Naoto Umeda [Japon] ; Yuya Kondo [Japon] ; Hiroto Tsuboi [Japon] ; Isao Matsumoto [Japon] ; Takayuki Sumida [Japon] | Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept. |
| 001C14 (2016) |
Amir Hashemi-Meshkini [Iran] ; Shekoufeh Nikfar [Iran] ; Elizabeth Glaser [États-Unis] ; Ahmadreza Jamshidi [Iran] ; Seyed Alireza Hosseini [Iran] | Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model. |
| 001C16 (2016) |
Matt Stevenson [Royaume-Uni] ; Rachel Archer [Royaume-Uni] ; Jon Tosh [Royaume-Uni] ; Emma Simpson [Royaume-Uni] ; Emma Everson-Hock [Royaume-Uni] ; John Stevens [Royaume-Uni] ; Monica Hernandez-Alava [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Kath Dickinson [Royaume-Uni] ; David Scott [Royaume-Uni] ; Adam Young [Royaume-Uni] ; Allan Wailoo [Royaume-Uni] | Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. |
| 001C18 (2016) |
Keisuke Izumi ; Yuko Kaneko ; Misato Hashizume ; Keiko Yoshimoto ; Tsutomu Takeuchi | Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). |
| 001C49 (2016) |
M. Beck [France] ; B. Michel [France] ; M-C Rybarczyk-Vigouret [France] ; C. Sordet [France] ; J. Sibilia [France] ; M. Velten [France] | Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings? |
| 001C81 (2016) |
Matt Stevenson [Royaume-Uni] ; Rachel Archer [Royaume-Uni] ; Jon Tosh [Royaume-Uni] ; Emma Simpson [Royaume-Uni] ; Emma Everson-Hock [Royaume-Uni] ; John Stevens [Royaume-Uni] ; Monica Hernandez-Alava [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Kath Dickinson [Royaume-Uni] ; David Scott [Royaume-Uni] ; Adam Young [Royaume-Uni] ; Allan Wailoo [Royaume-Uni] | Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. |
| 002107 (2015) |
Keisuke Izumi [Japon] ; Yuko Kaneko [Japon] ; Misato Hashizume [Japon] ; Keiko Yoshimoto [Japon] ; Tsutomu Takeuchi [Japon] | Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). |
| 002449 (2014) |
Petra Baji [Hongrie] ; Márta Péntek ; Lászl Czirják ; Zoltán Szekanecz ; György Nagy ; Lászl Gulácsi ; Valentin Brodszky | Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. |
